HCW Biologics(HCWB)
$0.80-0.06 (-6.98%)
HCWB
HCW Biologics financials statements
$0.80
At close:-0.06 (-6.98%)
Want to see HCWB full AI Analyst Report?
HCW Biologics (HCWB) Ratios
264 Followers
HCW Biologics Ratios
HCWB's free cash flow for Q2 2026 was $-3.97M. For the 2026 fiscal year, HCWB's free cash flow was increased by $4.00 and operating cash flow was $-3.97M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.11 | 0.19 | 0.73 | 11.52 | 17.44 |
| Quick Ratio | 0.11 | 0.19 | 0.73 | 11.05 | 17.44 |
| Cash Ratio | 0.09 | 0.16 | 0.41 | 7.55 | 5.05 |
| Solvency Ratio | -0.32 | -0.78 | -1.59 | -1.51 | -5.31 |
| Operating Cash Flow Ratio | -0.64 | -0.48 | -2.57 | -3.51 | -4.73 |
| Short-Term Operating Cash Flow Coverage | -1.97 | -2.25 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -19.47M | $ -31.31M | $ -8.65M | $ 24.69M | $ 38.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.45 | 0.22 | 0.14 | 0.00 |
| Debt-to-Equity Ratio | 2.46 | -2.02 | 0.47 | 0.17 | 0.00 |
| Debt-to-Capital Ratio | 0.71 | 1.98 | 0.32 | 0.15 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 12.14 | 0.32 | 0.15 | 0.00 |
| Financial Leverage Ratio | 8.87 | -4.47 | 2.12 | 1.25 | 1.05 |
| Debt Service Coverage Ratio | -0.70 | -3.70 | -83.30 | -110.98 | 0.00 |
| Interest Coverage Ratio | -9.00 | -25.45 | -90.86 | -119.05 | 0.00 |
| Debt to Market Cap | 3.35 | 0.02 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 23.05 | 2.30 | 0.18 | 0.18 | 0.00 |
| Net Debt to EBITDA | -0.86 | -0.33 | -0.11 | 1.13 | 0.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 20.00% | 37.38% | 19.72% | 38.48% | 0.00% |
| EBIT Margin | -12371.73% | -1124.57% | -869.56% | -219.78% | 0.00% |
| EBITDA Margin | -10450.78% | -1078.43% | -829.62% | -209.10% | 0.00% |
| Operating Profit Margin | -20757.65% | -1148.50% | -904.96% | -224.32% | 0.00% |
| Pretax Profit Margin | -14677.14% | -1169.70% | -879.52% | -221.67% | 0.00% |
| Net Profit Margin | -14677.14% | -1169.70% | -879.52% | -221.67% | 0.00% |
| Continuous Operations Profit Margin | -14677.14% | -1169.70% | -879.52% | -221.67% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 70.71% | 101.85% | 97.19% | 98.82% | 96.22% |
| Return on Assets (ROA) | -32.46% | -99.30% | -87.66% | -31.83% | -24.04% |
| Return on Equity (ROE) | -287.90% | 443.47% | -185.67% | -39.81% | -25.13% |
| Return on Capital Employed (ROCE) | -325.61% | -4851.08% | -130.11% | -34.39% | -26.11% |
| Return on Invested Capital (ROIC) | -109.65% | -425.86% | -130.11% | -34.39% | -26.11% |
| Return on Tangible Assets | -32.46% | -99.30% | -87.66% | -31.83% | -24.04% |
| Earnings Yield | -391.18% | -4.34% | -1.41% | -0.54% | -0.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.69 | 4.41 | 1.85 | 16.09 | 0.00 |
| Payables Turnover | 0.00 | 0.07 | 0.37 | 3.37 | 2.43 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 2.96 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.11 | 0.14 | 0.62 | 0.00 |
| Asset Turnover | 0.00 | 0.08 | 0.10 | 0.14 | 0.00 |
| Working Capital Turnover Ratio | -0.00 | -0.20 | 0.20 | 0.19 | 0.00 |
| Cash Conversion Cycle | -110356.88 | -4988.34 | -789.42 | 37.57 | -150.18 |
| Days of Sales Outstanding | 216.55 | 82.79 | 197.25 | 22.68 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 123.11 | 0.00 |
| Days of Payables Outstanding | 110573.43 | 5071.13 | 986.68 | 108.22 | 150.18 |
| Operating Cycle | 216.55 | 82.79 | 197.25 | 145.79 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -38.30 | -2.20 | -0.63 | -0.29 | -0.31 |
| Free Cash Flow Per Share | -38.30 | -2.24 | -0.80 | -0.58 | -0.31 |
| Dividend Paid and CapEx Coverage Ratio | -4463872.33 | -54.38 | -3.63 | -1.01 | -232.23 |
| Capital Expenditure Coverage Ratio | -4463872.33 | -54.38 | -3.63 | -1.01 | -232.23 |
| Operating Cash Flow Coverage Ratio | -1.97 | -1.04 | -3.57 | -1.62 | 0.00 |
| Operating Cash Flow to Sales Ratio | -246.93 | -5.54 | -7.92 | -1.55 | 0.00 |
| Free Cash Flow Yield | -658.14% | -2.09% | -1.62% | -0.75% | -0.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.09 | -23.17 | -70.73 | -184.13 | -258.06 |
| Price-to-Sales (P/S) Ratio | 37.52 | 269.62 | 622.05 | 408.15 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.74 | -102.22 | 131.32 | 73.30 | 64.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.15 | -47.76 | -61.56 | -132.79 | -301.13 |
| Price-to-Operating Cash Flow Ratio | -0.15 | -48.64 | -78.52 | -264.16 | -302.42 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -2.32 | -1.00 | -10.74 | -2.17 |
| Enterprise Value Multiple | -1.22 | -25.33 | -75.09 | -194.06 | -268.50 |
| Enterprise Value | 6.89M | 701.09M | 1.77B | 2.73B | 3.31B |
| EV to EBITDA | -1.22 | -25.33 | -75.09 | -194.06 | -268.50 |
| EV to Sales | 127.07 | 273.14 | 623.00 | 405.78 | 0.00 |
| EV to Free Cash Flow | -0.51 | -48.39 | -61.65 | -132.02 | -300.06 |
| EV to Operating Cash Flow | -0.51 | -49.28 | -78.64 | -262.63 | -301.35 |
| Tangible Book Value Per Share | 7.91 | -1.05 | 0.37 | 1.04 | 1.43 |
| Shareholders’ Equity Per Share | 7.91 | -1.05 | 0.37 | 1.04 | 1.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.16 | 0.40 | 0.08 | 0.19 | 0.00 |
| Net Income Per Share | -22.77 | -4.64 | -0.70 | -0.42 | -0.36 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.19 | 1.04 | 1.01 | 1.01 | 1.00 |
| Research & Development to Revenue | 100.36 | 2.49 | 2.70 | 1.39 | 0.00 |
| SG&A to Revenue | 142.01 | 8.55 | 4.60 | 1.19 | 0.00 |
| Stock-Based Compensation to Revenue | 14.17 | 0.39 | 0.35 | 0.17 | 0.00 |
| Income Quality | 1.68 | 0.47 | 0.90 | 0.70 | 0.85 |
Currency in USD
